Huahai Pharmaceutical (600521.SH) subsidiary HB0025 injection has started Phase III clinical trials.

Zhixin Finance APP News, Huahai Pharmaceutical (600521.SH) announced that its subsidiary Shanghai Hua'ao Tai Biotechnology Co., Ltd. ("Hua'ao Tai") recently held a meeting with the National Medical Products Administration Drug Evaluation Center (CDE) regarding the Phase II clinical trial of HB0025 in combination with first-line chemotherapy for squamous and non-squamous non-small cell lung cancer. The company will officially start the Phase III clinical trial of HB0025 injection.